Serving one of the key therapeutic areas within the Russian Federation’s Government tendering process, Hemophilia, SG Biotech continues to build on its strong position during the first half of 2019. A study published by AlphaRM shows SG Biotech in fifth position with a growth rate of 8%. This follows the company’s excellent record in 2018, its initial year of operation and demonstrates our capacity to service this important treatment area.